Go to
JCI Insight
Citations to this article
Julia A. Wagner, … , Hing C. Wong, Todd A. Fehniger
Published October 3, 2017
Citation Information: J Clin Invest. 2017;127(11):4042-4058. https://doi.org/10.1172/JCI90387.
Citation Information: J Clin Invest. 2017;127(11):4042-4058. https://doi.org/10.1172/JCI90387.
Abstract
NK cells, lymphocytes of the innate immune system, are important for defense against infectious pathogens and cancer. Classically, the CD56dim NK cell subset is thought to mediate antitumor responses, whereas the CD56bright subset is involved in immunomodulation. Here, we challenge this paradigm by demonstrating that brief priming with IL-15 markedly enhanced the antitumor response of CD56bright NK cells. Priming improved multiple CD56bright cell functions: degranulation, cytotoxicity, and cytokine production. Primed CD56bright cells from leukemia patients demonstrated enhanced responses to autologous blasts in vitro, and primed CD56bright cells controlled leukemia cells in vivo in a murine xenograft model. Primed CD56bright cells from multiple myeloma (MM) patients displayed superior responses to autologous myeloma targets, and furthermore, CD56bright NK cells from MM patients primed with the IL-15 receptor agonist ALT-803 in vivo displayed enhanced ex vivo functional responses to MM targets. Effector mechanisms contributing to IL-15–based priming included improved cytotoxic protein expression, target cell conjugation, and LFA-1–, CD2-, and NKG2D-dependent activation of NK cells. Finally, IL-15 robustly stimulated the PI3K/Akt/mTOR and MEK/ERK pathways in CD56bright compared with CD56dim NK cells, and blockade of these pathways attenuated antitumor responses. These findings identify CD56bright NK cells as potent antitumor effectors that warrant further investigation as a cancer immunotherapy.
Authors
Julia A. Wagner, Maximillian Rosario, Rizwan Romee, Melissa M. Berrien-Elliott, Stephanie E. Schneider, Jeffrey W. Leong, Ryan P. Sullivan, Brea A. Jewell, Michelle Becker-Hapak, Timothy Schappe, Sara Abdel-Latif, Aaron R. Ireland, Devika Jaishankar, Justin A. King, Ravi Vij, Dennis Clement, Jodie Goodridge, Karl-Johan Malmberg, Hing C. Wong, Todd A. Fehniger
Total citations by year
Citation information
Citations to this article (183)
| Title and authors | Publication | Year |
|---|---|---|
|
A Mitochondria‐Related Signature in Diffuse Large B‐Cell Lymphoma: Prognosis, Immune and Therapeutic Features
Zhou Z, Lu J, Guo S, Tian X, Li H, Zhou H, Huang W |
Cancer Medicine | 2025 |
|
The characteristics of the tumor immune microenvironment in colorectal cancer with different MSI status and current therapeutic strategies
Wang Q, Yu M, Zhang S |
Frontiers in Immunology | 2025 |
|
Reversing NK cell exhaustion: a novel strategy combining immune checkpoint blockade with drug sensitivity enhancement in the treatment of hepatocellular carcinoma
Huang Y, Liao H, Luo J, Wei H, Li A, Lu Y, Xiang B |
Frontiers in Oncology | 2025 |
|
CD56bright cytokine-induced memory-like NK cells and NK-cell engagers synergize against non-small cell lung cancer cancer-stem cells
Guevara Lopez ML, Gebo A, Parodi M, Persano S, Maus-Conn J, Mingari MC, Loiacono F, Orecchia P, Sivori S, Cantoni C, Gentili M, Facchinetti F, Ferracini R, Vallera DA, Felices M, Bertolini G, Pravetoni M, Roz L, Vitale M |
Journal for Immunotherapy of Cancer | 2025 |
|
Memory-like NK cell differentiation, inhibitory NKG2A blockade, and improved recognition via antibody or CAR engineering combine to enhance NK cell attack against multiple myeloma
Zhou AY, Marin ND, Afrin S, Wong P, Tran J, Jacobs MT, Becker-Hapak M, Marsala L, Foster M, Foltz JA, Neal CC, Russler-Germain DA, Morina L, Paik Y, Cubitt CC, Schappe T, Pence P, McClain E, Kelley S, Fortier J, Fiala M, Slade M, Schroeder M, Stockerl-Goldstein K, Vij R, Gao F, Berrien-Elliott MM, Fehniger TA |
The Journal of Immunology Author Choice | 2025 |
|
CD103+CD56+ ILCs Are Associated with an Altered CD8+ T-cell Profile within the Tumor Microenvironment
Chung DC, Shakfa N, Vakharia J, Warner K, Jacquelot N, Sayad A, Han S, Ghaedi M, Garcia-Batres CR, Sotty J, Azarmina A, Nowlan F, Chen EL, Zon M, Elford AR, Wang BX, Nguyen LT, Mrkonjic M, Clarke BA, Bernardini MQ, Haibe-Kains B, Ferguson SE, Crome SQ, Jackson HW, Ohashi PS |
Cancer Immunology Research | 2025 |
|
Engineering innate immune cells for cancer immunotherapy.
Tarannum M, Ding X, Barisa M, Hu S, Anderson J, Romee R, Zhang J |
Nature biotechnology | 2025 |
|
Diagnostic, prognostic, and immunological roles of FUT8 in lung adenocarcinoma and lung squamous cell carcinoma
Li Z, Zhu Z, Wang P, Hou C, Ren L, Xu D, Wang X, Guo F, Meng Q, Liang W, Xue J, Zhi X |
PLOS One | 2025 |
|
Tumor-infiltrating lymphocytes in cancer immunotherapy: from chemotactic recruitment to translational modeling
Kraja FP, Jurisic VB, Hromić-Jahjefendić A, Rossopoulou N, Katsila T, Mirjacic Martinovic K, De Las Rivas J, Diaconu CC, Szöőr Á |
Frontiers in Immunology | 2025 |
|
Innate Lymphoid Cells in Inflammatory Bowel Disease
Yao X, Ma K, Zhu Y, Cao S |
Cells | 2025 |
|
CD56 on intratumoral NK cells: orchestrating NK cell-mediated anti-tumor effects in bladder cancer
Hassouneh Z, Noel OD, Ji N, Kim ME, Bowman N, Svatek RS, Mace E, Mukherjee N |
Neoplasia (New York, N.Y.) | 2025 |
|
IPSC-derived NK cells for immunotherapy and therapeutic perspective (Review)
Wei X, Su C, Liu Y, Wei N, Xiang K, Qian Q, Xu Z |
Molecular Medicine Reports | 2025 |
|
Combined IL6 and CCR2 Blockade Potentiates Antitumor Activity of NK Cells in HPV-Negative Head and Neck Cancer
Yong Teng, Chenyang Yuan, Fanghui Chen, Zhaohui Qin, Nicole Schmitt, Gregory Lesinski, Nabil Saba, Yong Teng |
Journal of experimental & clinical cancer research : CR | 2024 |
|
Clearing soluble MIC reverses the impaired function of natural killer cells from patients with multiple myeloma.
Kim S, Chung H, Kwak JE, Kim YR, Park CH, Kim Y, Cheong JW, Wu J, Shin EC, Cho H, Kim JS |
Journal for ImmunoTherapy of Cancer | 2024 |
|
Combined use of NK cells and radiotherapy in the treatment of solid tumors
Zheng W, Ling S, Cao Y, Shao C, Sun X |
Frontiers in immunology | 2024 |
|
Signalling mechanisms driving homeostatic and inflammatory effects of interleukin-15 on tissue lymphocytes
Skariah N, James OJ, Swamy M |
2024 | |
|
Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy
Maia A, Tarannum M, Lérias JR, Piccinelli S, Borrego LM, Maeurer M, Romee R, Castillo-Martin M |
Cells | 2024 |
|
Research Progress of Nanomaterials Acting on NK Cells in Tumor Immunotherapy and Imaging
Feng Y, Zhang H, Shao J, Du C, Zhou X, Guo X, Wang Y |
Biology | 2024 |
|
Thymic NK-Cells and Their Potential in Cancer Immunotherapy
Forbes C, Nierkens S, Cornel AM |
ImmunoTargets and Therapy | 2024 |
|
Crosstalk Between NK Cell Receptors and Tumor Membrane Hsp70‐Derived Peptide: A Combined Computational and Experimental Study
Yazdi M, Hasanzadeh Kafshgari M, Khademi Moghadam F, Zarezade V, Oellinger R, Khosravi M, Haas S, Hoch CC, Pockley AG, Wagner E, Wollenberg B, Multhoff G, Bashiri Dezfouli A |
Advanced Science | 2024 |
|
The Role of Natural Killer Cells in the Tumor Immune Microenvironment of EBV-Associated Nasopharyngeal Carcinoma.
Li S, Dai W, Kam NW, Zhang J, Lee VHF, Ren X, Kwong DL |
Cancers | 2024 |
|
Tissue Resident Memory NK cells: homing in on local effectors and regulators
Schuster IS, Andoniou CE, Degli-Esposti MA |
Immunological Reviews | 2024 |
|
A novel prognostic signature based on smoking-associated genes for predicting prognosis and immune microenvironment in NSCLC smokers.
Li Q, Wang T, Tang Y, Zou X, Shen Z, Tang Z, Zhou Y, Shi J |
Cancer Cell International | 2024 |
|
BCG priming followed by a novel interleukin combination activates Natural Killer cells to selectively proliferate and become anti-tumour long-lived effectors
Felgueres MJ, Esteso G, García-Jiménez ÁF, Dopazo A, Aguiló N, Mestre-Durán C, Martínez-Piñeiro L, Pérez-Martínez A, Reyburn HT, Valés-Gómez M |
Scientific Reports | 2024 |
|
Changes in subset distribution and impaired function of circulating natural killer cells in patients with colorectal cancer
Zu S, Lu Y, Xing R, Chen X, Zhang L |
Scientific Reports | 2024 |
|
Striking a balance: The Goldilocks of CD8 expression on NK cells
Paarth B. Dodhiawala1, Frank Cichocki1 |
Journal of Clinical Investigation | 2024 |
|
A “Prime and Expand” strategy using the multifunctional fusion proteins to generate memory-like NK cells for cell therapy
Shrestha N, Dee MJ, Chaturvedi P, Leclerc GM, Mathyer M, Dufour C, Arthur L, Becker-Hapak M, Foster M, McClain E, Pena NV, Kage K, Zhu X, George V, Liu B, Egan J, Echeverri C, Wang M, You L, Kong L, Li L, Berrien-Elliott MM, Cooper ML, Fehniger TA, Rhode PR, Wong HC |
Cancer Immunology, Immunotherapy | 2024 |
|
Natural Killer-Based Therapy: A Prospective Thought for Cancer Treatment Related to Diversified Drug Delivery Pathways
Zang J, Mei Y, Zhu S, Yin S, Feng N, Ci T, Lyu Y |
Pharmaceutics | 2024 |
|
RBBP4: A novel diagnostic and prognostic biomarker for non‐small‐cell lung cancer correlated with autophagic cell death
Zhan Y, Zhang Z, Yin A, Su X, Tang N, Chen Y, Zhang Z, Chen W, Wang J, Wang W |
Cancer Medicine | 2024 |
|
Natural Killer cells at the frontline in the fight against cancer
Coënon L, Geindreau M, Ghiringhelli F, Villalba M, Bruchard M |
Cell Death & Disease | 2024 |
|
ZFP1 is a biomarker related to poor prognosis and immunity in gastric cancer.
Yao J, Ma F, Shi D, Da M |
Scientific reports | 2024 |
|
Defects in NK cell immunity of pediatric cancer patients revealed by deep immune profiling
Syrimi E, Khan N, Murray P, Willcox C, Haigh T, Willcox B, Masand N, Bowen C, Dimakou DB, Zuo J, Barone SM, Irish JM, Kearns P, Taylor GS |
iScience | 2024 |
|
Prospective Molecular Targets for Natural Killer Cell Immunotherapy against Glioblastoma Multiforme
Cooksey LC, Friesen DC, Mangan ED, Mathew PA |
Cells | 2024 |
|
Bulk and single-cell transcriptomics identify gene signatures of stem cell-derived NK cell donors with superior cytolytic activity
van Vliet AA, van den Hout MG, Steenmans D, Duru AD, Georgoudaki AM, de Gruijl TD, van IJcken WF, Spanholtz J, Raimo M |
Molecular Therapy Oncology | 2024 |
|
CAR immunotherapy in autoimmune diseases: promises and challenges.
Yu J, Yang Y, Gu Z, Shi M, La Cava A, Liu A |
Frontiers in immunology | 2024 |
|
N-803, an IL-15 Superagonist Complex as Maintenance Therapy After Allogeneic Donor Stem Cell Transplant for Acute Myeloid Leukemia or Myelodysplastic Syndrome; A Phase 2 Trial
Merino A, Brunstein CC, Shanley R, Rashid F, Wangen R, Bachanova V, Juckett M, Maakaron J, Felices M, Weisdorf D, Miller JS |
Transplantation and cellular therapy | 2024 |
|
Synaptotagmin-like protein 1 is a potential diagnostic and prognostic biomarker in endometrial cancer based on bioinformatics and experiments
Meijuan C, Meng X, Fang L, Qian W |
Journal of Ovarian Research | 2023 |
|
A Subset of PD-1-Expressing CD56bright NK Cells Identifies Patients with Good Response to Immune Checkpoint Inhibitors in Lung Cancer
Gascón-Ruiz M, Ramírez-Labrada A, Lastra R, Martínez-Lostao L, Paño-Pardo JR, Sesma A, Zapata-García M, Moratiel A, Quílez E, Torres-Ramón I, Yubero A, Domingo MP, Esteban P, Gálvez EM, Pardo J, Isla D |
Cancers | 2023 |
|
Metabolic regulation of NK cell function: implications for immunotherapy
Sohn H, Cooper MA |
2023 | |
|
Unwinding the Role of the CMG Helicase in Inborn Errors of Immunity.
Guilz NC, Ahn YO, Seo S, Mace EM |
Journal of Clinical Immunology | 2023 |
|
A network pharmacology-based investigation of emodin against pancreatic adenocarcinoma
Shi X, Huang B, Zhu J, Yamaguchi T, Hu A, Tabuchi M, Watanabe D, Yoshikawa S, Mizushima S, Mizushima A, Xia S |
Medicine | 2023 |
|
The role of tumor-infiltrating lymphocytes in triple-negative breast cancer and the research progress of adoptive cell therapy
Li R, Cao L |
Frontiers in immunology | 2023 |
|
Exploiting an Interleukin-15 Heterodimeric Agonist (N803) for Effective Immunotherapy of Solid Malignancies
Lui G, Minnar CM, Soon-Shiong P, Schlom J, Gameiro SR |
Cells | 2023 |
|
Therapies Targeting Immune Cells in Tumor Microenvironment for Non-Small Cell Lung Cancer.
Ye W, Li M, Luo K |
Pharmaceutics | 2023 |
|
MMP11 and MMP17 are potential biomarkers for uterine corpus endometrial carcinoma prognosis.
Zhang Y, Wang J, Fan Y, Lang F, Fu F, Liu Q |
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2023 |
|
Chimeric antigen receptor engineered natural killer cells for cancer therapy.
Zhang Y, Zhou W, Yang J, Yang J, Wang W |
Experimental Hematology and Oncology | 2023 |
|
Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity.
Faber ML, Oldham RAA, Thakur A, Rademacher MJ, Kubicka E, Dlugi TA, Gifford SA, McKillop WM, Schloemer NJ, Lum LG, Medin JA |
Frontiers in immunology | 2023 |
|
CD56bright natural killer cells preferentially kill proliferating CD4+ T cells
Lee M, Bell CJ, Rubio Garcia A, Godfrey L, Pekalski M, Wicker LS, Todd JA, Ferreira RC |
2023 | |
|
NK Cells from HCMV Seropositive Individuals Have a Distinct Metabolic Profile that Correlates with Elevated mTOR Signaling
Lozada JR, Zhang B, Miller JS, Cichocki F |
Journal of immunology (Baltimore, Md. : 1950) | 2023 |
|
The construction of a prognostic model of cervical cancer based on four immune-related LncRNAs and an exploration of the correlations between the model and oxidative stress
Lv X, Jia Y, Li J, Deng S, Yuan E |
Frontiers in pharmacology | 2023 |
|
Engineering NK-CAR.19 cells with the IL-15/IL-15Rα complex improved proliferation and anti-tumor effect in vivo
Silvestre RN, Eitler J, de Azevedo JT, Tirapelle MC, Fantacini DM, de Souza LE, Swiech K, Covas DT, Calado RT, Montero PO, Malmegrim KC, Figueiredo ML, Tonn T, Picanço-Castro V |
Frontiers in immunology | 2023 |
|
Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function
Zhang C, Kadu S, Xiao Y, Johnson O, Kelly A, O'Connor RS, Lai M, Kong H, Srivatsa S, Tai V, Greenblatt E, Holmes M, Riley JL, June CH, Sheppard NC |
Cancer immunology research | 2023 |
|
NK Cell Therapeutics for Hematologic Malignancies: from Potential to Fruition.
Fetzko SL, Timothy LD, Parihar R |
Current Hematologic Malignancy Reports | 2023 |
|
Immune microenvironment dynamics of HER2 overexpressing breast cancer under dual anti-HER2 blockade
Batalha S, Gomes CM, Brito C |
Frontiers in immunology | 2023 |
|
High USP32 expression contributes to cancer progression and is correlated with immune infiltrates in hepatocellular carcinoma
Xiu M, Bao W, Wang J, Chen J, Li Y, Hai Y |
BMC Cancer | 2023 |
|
Deep phenotyping characterization of human unconventional CD8+NKG2A/C+ T cells among T and NK cells by spectral flow cytometry
Orta-Resendiz A, Petitdemange C, Schmutz S, Jacquelin B, Novault S, Huot N, Müller-Trutwin M |
2023 | |
|
Exploiting autophagy balance in T and NK cells as a new strategy to implement adoptive cell therapies
Giansanti M, Theinert T, Boeing SK, Haas D, Schlegel PG, Vacca P, Nazio F, Caruana I |
Molecular Cancer | 2023 |
|
Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy
Fantini M, Arlen PM, Tsang KY |
Frontiers in immunology | 2023 |
|
IL-15 Priming Alters IFN-γ Regulation in Murine NK Cells.
Cimpean M, Keppel MP, Gainullina A, Fan C, Sohn H, Schedler NC, Swain A, Kolicheski A, Shapiro H, Young HA, Wang T, Artyomov MN, Cooper MA |
Journal of immunology (Baltimore, Md. : 1950) | 2023 |
|
Metabolic regulation of NK cell antiviral functions during cytomegalovirus infection
Cimpean M, Cooper MA |
Journal of leukocyte biology | 2023 |
|
The combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer
Zhenghang Wang, Qi Zhang, Changsong Qi, Yuezong Bai, Feilong Zhao, Hui Chen, Zhongwu Li, Xicheng Wang, Mifen Chen, Jifang Gong, Zhi Peng, Xiaotian Zhang, Jinping Cai, Shiqing Chen, Xiaochen Zhao, Lin Shen, Jian Li |
Journal for ImmunoTherapy of Cancer | 2022 |
|
An ELF4 hypomorphic variant results in NK cell deficiency
Sandra Salinas, Emily Mace, Matilde Conte, Chun Park, Yu Li, Joshua Rosario-Sepulveda, Sanjana Mahapatra, Emily Moore, Evelyn Hernandez, Ivan K. Chinn, Abigail Reed, Barclay Lee, Alexander Frumovitz, Richard Gibbs, Jennifer E. Posey, Lisa Forbes Satter, Akaluck Thatayatikom, Eric Allenspach, Theodore G. Wensel, James Lupski, H Daniel Lacorazza, Jordan Orange |
JCI Insight | 2022 |
|
Phenotypic and Functional Plasticity of CXCR6+ Peripheral Blood NK Cells
L Angelo, G Hogg, S Abeynaike, L Bimler, A Vargas-Hernandez, S Paust |
Frontiers in immunology | 2022 |
|
Single-cell transcriptome profiling reveals the key role of ZNF683 in NK cell exhaustion in myeloma
Xin Li, Mengping Chen, Yike Wan, Lu Zhong, Xiaofeng Han, Xiaotong Chen, Fei Xiao, Jia Liu, Yiwei Zhang, Di Zhu, Junling Liu, Honghui Huang, Jian Hou |
Clinical and Translational Medicine | 2022 |
|
Roles of natural killer cells in immunity to cancer, and applications to immunotherapy
N Wolf, D Kissiov, D Raulet |
Nature Reviews Immunology | 2022 |
|
Natural Killer Cells in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - A Review of the Literature
S Fuchs, A Scheffschick, I Gunnarsson, H Brauner |
Frontiers in immunology | 2022 |
|
Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy
Z Bai, Y Zhou, Z Ye, J Xiong, H Lan, F Wang |
Frontiers in immunology | 2022 |
|
PDGF-D−PDGFRβ signaling enhances IL-15–mediated human natural killer cell survival
S Ma, T Tang, X Wu, A Mansour, T Lu, J Zhang, L Wang, M Caligiuri, J Yu |
Proceedings of the National Academy of Sciences | 2022 |
|
Dendritic cell-based vaccine prolongs survival and time to next therapy independently of the vaccine cell number
S Hawlina, H Chowdhury, T Smrkolj, R Zorec |
Biology direct | 2022 |
|
A novel fusion protein scaffold 18/12/TxM activates the IL-12, IL-15, and IL-18 receptors to induce human memory-like natural killer cells
C Cubitt, E McClain, M Becker-Hapak, J Foltz, P Wong, J Wagner, C Neal, N Marin, L Marsala, M Foster, T Schappe, P Soon-Shiong, J Lee, M Berrien-Elliott, T Fehniger |
Molecular Therapy — Oncolytics | 2022 |
|
Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients
D Yue, W Liu, C Chen, T Zhang, Y Ma, L Cui, Y Gu, T Bei, X Zhao, B Zhang, Y Bai, A Romero, M Xu-Welliver, C Wang, Z Zhang, B Zhang |
Translational Lung Cancer Research | 2022 |
|
A Novel Sushi-IL15-PD1 CAR-NK92 Cell Line With Enhanced and PD-L1 Targeted Cytotoxicity Against Pancreatic Cancer Cells
D Xu, Y He, B Xiao, Y Si, J Shi, X Liu, L Tian, Q Ren, Y Wu, Y Zhu |
Frontiers in Oncology | 2022 |
|
Cytotoxic innate lymphoid cells sense cancer cell-expressed interleukin-15 to suppress human and murine malignancies.
Kansler ER, Dadi S, Krishna C, Nixon BG, Stamatiades EG, Liu M, Kuo F, Zhang J, Zhang X, Capistrano K, Blum KA, Weiss K, Kedl RM, Cui G, Ikuta K, Chan TA, Leslie CS, Hakimi AA, Li MO |
Nature Immunology | 2022 |
|
High MICAL-L2 expression and its role in the prognosis of colon adenocarcinoma.
Yang Y, Ye F, Xia T, Wang Q, Zhang Y, Du J |
BMC Cancer | 2022 |
|
CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk.
Baer C, Kimura S, Rana MS, Kleist AB, Flerlage T, Feith DJ, Chockley P, Walter W, Meggendorfer M, Olson TL, Cheon H, Olson KC, Ratan A, Mueller ML, Foran JM, Janke LJ, Qu C, Porter SN, Pruett-Miller SM, Kalathur RC, Haferlach C, Kern W, Paietta E, Thomas PG, Babu MM, Loughran TP Jr, Iacobucci I, Haferlach T, Mullighan CG |
Nature Genetics | 2022 |
|
Mesenchymal stem cells-based therapy in liver diseases
Han HT, Jin WL, Li X |
2022 | |
|
Increased expression of MMP17 predicts poor clinical outcomes in epithelial ovarian cancer patients
Xiao C, Wang Y, Cheng Q, Fan Y |
Medicine | 2022 |
|
CD160 Promotes NK Cell Functions by Upregulating Glucose Metabolism and Negatively Correlates With HIV Disease Progression.
Sun Z, Li Y, Zhang Z, Fu Y, Han X, Hu Q, Ding H, Shang H, Jiang Y |
Frontiers in immunology | 2022 |
|
The soldiers needed to be awakened: Tumor-infiltrating immune cells
Yaping W, Zhe W, Zhuling C, Ruolei L, Pengyu F, Lili G, Cheng J, Bo Z, Liuyin L, Guangdong H, Yaoling W, Niuniu H, Rui L |
Frontiers in Genetics | 2022 |
|
Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy.
Ma S, Caligiuri MA, Yu J |
Trends in Immunology | 2022 |
|
SOT101 induces NK cell cytotoxicity and potentiates antibody-dependent cell cytotoxicity and anti-tumor activity.
Antosova Z, Podzimkova N, Tomala J, Augustynkova K, Sajnerova K, Nedvedova E, Sirova M, de Martynoff G, Bechard D, Moebius U, Kovar M, Spisek R, Adkins I |
Frontiers in immunology | 2022 |
|
Natural killer cells in clinical development as non-engineered, engineered, and combination therapies.
Lamers-Kok N, Panella D, Georgoudaki AM, Liu H, Özkazanc D, Kučerová L, Duru AD, Spanholtz J, Raimo M |
Journal of Hematology & Oncology | 2022 |
|
Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse
Berdel AF, Ruhnke L, Angenendt L, Wermke M, Röllig C, Mikesch JH, Scheller A, Hemmerle T, Matasci M, Wethmar K, Kessler T, Gerwing M, Hescheler D, Schäfers M, Hartmann W, Altvater B, Rossig C, Bornhäuser M, Lenz G, Stelljes M, Rueter B, Neri D, Berdel WE, Schliemann C |
Blood Advances | 2022 |
|
BCG-activation of leukocytes is sufficient for the generation of donor-independent innate anti-tumor NK and γδ T-cells that can be further expanded in vitro
Esteso G, Felgueres MJ, García-Jiménez ÁF, Reyburn-Valés C, Benguría A, Vázquez E, Reyburn HT, Aguiló N, Martín C, Puentes E, Murillo I, Rodríguez E, Valés-Gómez M |
OncoImmunology | 2022 |
|
Inflammatory-driven NK cell maturation and its impact on pathology.
Bourayou E, Golub R |
Frontiers in immunology | 2022 |
|
Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15
Fernandez RA, Mayoral JE, Pierre-Louis L, Yao Y, Xu Y, Mu S, Martinez-Lopez J, Primo D, Miyazaki T, Prabhala R, Anderson KC, Overwijk WW, Munshi NC, Fulciniti M |
Blood Advances | 2022 |
|
Cimigenol depresses acute myeloid leukemia cells protected by breaking bone marrow stromal cells via CXCR4/SDF‑1α
Ma B, Dai H, Dai X, Qian S, Sha X, Sun X |
Experimental and therapeutic medicine | 2022 |
|
Human natural killer cells: form, function, and development
Mace EM |
Journal of Allergy and Clinical Immunology | 2022 |
|
Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors
Ghaedrahmati F, Esmaeil N, Abbaspour M |
2022 | |
|
An Interleukin-15 Superagonist Enables Antitumor Efficacy of Natural Killer Cells Against All Molecular Variants of SCLC
Fousek K, Horn LA, Qin H, Dahut M, Iida M, Yacubovich D, Hamilton DH, Thomas A, Schlom J, Palena C |
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2022 |
|
Allogeneic natural killer cell therapy
Berrien-Elliott MM, Jacobs MT, Fehniger TA |
Blood | 2022 |
|
Safety switch optimization enhances antibody-mediated elimination of CAR T cells
Shabaneh TB, Moffett HF, Stull SM, Derezes T, Tait LJ, Park S, Riddell SR, Lajoie MJ |
2022 | |
|
NK and CD8 T cell phenotypes predict onset and control of CMV viremia post-kidney transplant
Harry Pickering, Subha Sen, Janice Arakawa-Hoyt, Kenichi Ishiyama, Yumeng Sun, Rajesh Parmar, Richard Ahn, Gema Sunga, Megan Llamas, Alexander Hoffmann, Mario Deng, Suphamai Bunnapradist, Joanna Schaenman, David Gjertson, Maura Rossetti, Lewis L Lanier, Elaine F. Reed |
JCI Insight | 2021 |
|
Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma
JA Foltz, BT Hess, V Bachanova, NL Bartlett, MM Berrien-Elliott, E McClain, M Becker-Hapak, M Foster, T Schappe, B Kahl, N Mehta-Shah, AF Cashen, ND Marin, K McDaniels, C Moreno, M Mosior, F Gao, OL Griffith, M Griffith, JA Wagner, N Epperla, AD Rock, J Lee, AA Petti, P Soon-Shiong, TA Fehniger |
Clinical cancer research | 2021 |
|
NK Cell Reconstitution After Autologous Hematopoietic Stem Cell Transplantation: Association Between NK Cell Maturation Stage and Outcome in Multiple Myeloma
A Orrantia, I Terrén, G Astarloa-Pando, C González, A Uranga, JJ Mateos-Mazón, JC García-Ruiz, M Riñón, M Rey, S Pérez-Fernandez, O Zenarruzabeitia, F Borrego |
Frontiers in immunology | 2021 |
|
Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide
B Rambaldi, HT Kim, C Reynolds, SC Rai, Y Arihara, T Kubo, L Buon, M Gooptu, J Koreth, C Cutler, S Nikiforow, VT Ho, EP Alyea, JH Antin, CJ Wu, RJ Soiffer, J Ritz, R Romee |
Blood Advances | 2021 |
|
Comparison of the composition of lymphocyte subpopulations in non-relapse and relapse patients with squamous cell carcinoma of the head and neck before, during radiochemotherapy and in the follow-up period: a multicenter prospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)
M Niu, SE Combs, A Linge, M Krause, M Baumann, F Lohaus, N Ebert, I Tinhofer, V Budach, J von der Grün, F Rödel, AL Grosu, G Multhoff |
Radiation Oncology | 2021 |
|
Natural Killer Cell Subpopulations and Inhibitory Receptor Dynamics in Myelodysplastic Syndromes and Acute Myeloid Leukemia
VA Cianga, LC Catafal, P Cianga, MP Tanasa, M Cherry, P Collet, E Tavernier, D Guyotat, C Rusu, CM Aanei |
Frontiers in immunology | 2021 |
|
Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy
S Gaggero, K Witt, M Carlsten, S Mitra |
Frontiers in immunology | 2021 |
|
Natural killer cells in antiviral immunity
NK Björkström, B Strunz, HG Ljunggren |
Nature Reviews Immunology | 2021 |
|
Making a Killer: Selecting the Optimal Natural Killer Cells for Improved Immunotherapies
SA Barnes, I Trew, E de Jong, B Foley |
Frontiers in immunology | 2021 |
|
Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment
RL Johnson, M Cummings, A Thangavelu, G Theophilou, D de Jong, NM Orsi |
Cancers | 2021 |
|
An Immunocompetent Microphysiological System to Simultaneously Investigate Effects of Anti-Tumor Natural Killer Cells on Tumor and Cardiac Microtissues
OT Nguyen, PM Misun, C Lohasz, J Lee, W Wang, T Schroeder, A Hierlemann |
Frontiers in immunology | 2021 |
|
Peripheral natural killer cells in chronic hepatitis B patients display multiple molecular features of T cell exhaustion
M Marotel, M Villard, A Drouillard, I Tout, L Besson, O Allatif, M Pujol, Y Rocca, M Ainouze, G Roblot, S Viel, M Gomez, V Loustaud, S Alain, D Durantel, T Walzer, U Hasan, A Marçais |
eLife | 2021 |
|
Natural Killer Anti-Tumor Activity Can Be Achieved by In Vitro Incubation With Heat-Killed BCG
G Esteso, N Aguiló, E Julián, O Ashiru, MM Ho, C Martín, M Valés-Gómez |
Frontiers in immunology | 2021 |
|
Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia
D Wang, N Wang, X Li, X Chen, B Shen, D Zhu, L Zhu, Y Xu, Y Yu, Y Shu |
Gastric Cancer | 2021 |
|
Human NK Cells in Autologous Hematopoietic Stem Cell Transplantation for Cancer Treatment
A Orrantia, I Terrén, G Astarloa-Pando, O Zenarruzabeitia, F Borrego |
Cancers | 2021 |
|
Biological bases of cancer immunotherapy
MM Carazas, JA Pinto, FL Casado |
Expert Reviews in Molecular Medicine | 2021 |
|
Staphylococcus aureus β-Hemolysin Up-Regulates the Expression of IFN-γ by Human CD56bright NK Cells
Z Guan, Y Liu, C Liu, H Wang, J Feng, G Yang |
Frontiers in Cellular and Infection Microbiology | 2021 |
|
NF-κB c-Rel Is Dispensable for the Development but Is Required for the Cytotoxic Function of NK Cells
Y Vicioso, DP Wong, NK Roy, N Das, K Zhang, P Ramakrishnan, R Parameswaran |
Frontiers in immunology | 2021 |
|
Extracellular mRNA transported to the nucleus exerts translation-independent function
T Tomita, M Kato, T Mishima, Y Matsunaga, H Sanjo, K Ito, K Minagawa, T Matsui, H Oikawa, S Takahashi, T Takao, N Iwai, T Mino, O Takeuchi, Y Maru, S Hiratsuka |
Nature Communications | 2021 |
|
Ovarian Cancer-Associated Ascites Have High Proportions of Cytokine-Responsive CD56bright NK Cells
CR Tonetti, CN de Souza-Araújo, A Yoshida, RF da Silva, PC Alves, TN Mazzola, S Derchain, LG Fernandes, F Guimarães |
Cells | 2021 |
|
Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment
J Kong, Y Qin, XS Zhao, Y Hou, K Liu, X Huang, H Jiang |
Annals of Hematology | 2021 |
|
Natural killer cell‑based immunotherapy for lung cancer: Challenges and perspectives (Review)
Y Zeng, X Lv, J Du |
Oncology reports | 2021 |
|
Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia
C Duault, A Kumar, AT Khani, SJ Lee, L Yang, M Huang, C Hurtz, B Manning, L Ghoda, T McDonald, NJ Lacayo, KM Sakamoto, M Carroll, SK Tasian, G Marcucci, J Yu, MA Caligiuri, HT Maecker, S Swaminathan |
Blood | 2021 |
|
Application of natural killer cells in pancreatic cancer (Review)
X Peng, L Chen, Y Jiao, Y Wang, Z Hao, X Zhan |
Oncology Letters | 2021 |
|
A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer
DA Vallera, F Oh, B Kodal, P Hinderlie, MA Geller, JS Miller, M Felices |
Cancers | 2021 |
|
A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy
MK Becker-Hapak, N Shrestha, E McClain, MJ Dee, P Chaturvedi, GM Leclerc, LI Marsala, M Foster, T Schappe, J Tran, S Desai, CC Neal, P Pence, P Wong, JA Wagner, DA Russler-Germain, X Zhu, CM Spanoudis, VL Gallo, CA Echeverri, LL Ramirez, L You, JO Egan, PR Rhode, J Jiao, GJ Muniz, EK Jeng, CA Prendes, RP Sullivan, MM Berrien-Elliott, HC Wong, TA Fehniger |
Cancer immunology research | 2021 |
|
CD127+ CD94+ innate lymphoid cells expressing granulysin and perforin are expanded in patients with Crohn’s disease
L Krabbendam, BA Heesters, CM Kradolfer, NJ Haverkate, MA Becker, CJ Buskens, WA Bemelman, JH Bernink, H Spits |
Nature Communications | 2021 |
|
A narrative review of central nervous system involvement in acute leukemias
D Deak, N Gorcea-Andronic, V Sas, P Teodorescu, C Constantinescu, S Iluta, S Pasca, I Hotea, C Turcas, V Moisoiu, AA Zimta, S Galdean, J Steinheber, I Rus, S Rauch, C Richlitzki, R Munteanu, A Jurj, B Petrushev, C Selicean, M Marian, O Soritau, A Andries, A Roman, D Dima, A Tanase, O Sigurjonsson, C Tomuleasa |
Annals of translational medicine | 2021 |
|
Sildenafil Citrate Downregulates PDE5A mRNA Expression in Women with Recurrent Pregnancy Loss without Altering Angiogenic Factors—A Preliminary Study
M Kniotek, A Roszczyk, M Zych, M Wrzosek, M Szafarowska, R Zagożdżon, M Jerzak |
Journal of Clinical Medicine | 2021 |
|
Identification of copy number variation-driven molecular subtypes informative for prognosis and treatment in pancreatic adenocarcinoma of a Chinese cohort
Q Zhan, C Wen, Y Zhao, L Fang, Y Jin, Z Zhang, S Zou, F Li, Y Yang, L Wu, J Jin, X Lu, J Xie, D Cheng, Z Xu, J Zhang, J Wang, XX Deng, H Chen, C Peng, H Li, H Zhang, H Fang, C Wang, B Shen |
EBioMedicine | 2021 |
|
Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma
G Yang, X Su, H Yang, G Luo, C Gao, Y Zheng, W Xie, M Huang, T Bei, Y Bai, Z Wang, P Cai, H He, J Xiang, M Cai, Y Zhang, C Qu, J Fu, Q Liu, Y Hu, J Zhong, Y Huang, Q Guo, X Zhang |
Annals of translational medicine | 2021 |
|
Thioredoxin activity confers resistance against oxidative stress in tumor-infiltrating NK cells
Ying Yang, Shi Yong Neo, Ziqing Chen, Weiyingqi Cui, Yi Chen, Min Guo, Yongfang Wang, Haiyan Xu, Annina Kurzay, Evren Alici, Lars Holmgren, Felix Haglund, Kai Wang, Andreas Lundqvist |
Journal of Clinical Investigation | 2020 |
|
Upregulation of Neural Cell Adhesion Molecule 1 (NCAM1) by hsa-miR-141-3p Suppresses Ameloblastoma Cell Migration
G Guan, X Niu, X Qiao, X Wang, J Liu, M Zhong |
Medical science monitor : international medical journal of experimental and clinical research | 2020 |
|
Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy
H Alfarra, J Weir, S Grieve, T Reiman |
Frontiers in immunology | 2020 |
|
Tumour microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC)
R Cao, L Yuan, B Ma, G Wang, Y Tian |
Cancer Immunology, Immunotherapy | 2020 |
|
Natural killer cells in cancer biology and therapy
SY Wu, T Fu, YZ Jiang, ZM Shao |
Molecular Cancer | 2020 |
|
Molecular Aspects and Future Perspectives of Cytokine-Based Anti-cancer Immunotherapy
DS Chulpanova, KV Kitaeva, AR Green, AA Rizvanov, VV Solovyeva |
Frontiers in Cell and Developmental Biology | 2020 |
|
Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-α
R Alves, SE McArdle, J Vadakekolathu, AC Gonçalves, P Freitas-Tavares, A Pereira, AM Almeida, AB Sarmento-Ribeiro, S Rutella |
Journal of Translational Medicine | 2020 |
|
Exploring the NK cell platform for cancer immunotherapy
JA Myers, JS Miller |
Nature Reviews Clinical Oncology | 2020 |
|
Patients’ NK cell stimulation with activated plasmacytoid dendritic cells increases dinutuximab-induced neuroblastoma killing
A Belounis, M Ayoub, P Cordeiro, W Lemieux, P Teira, E Haddad, S Herblot, M Duval |
Cancer Immunology, Immunotherapy | 2020 |
|
Design and Implementation of NK Cell-Based Immunotherapy to Overcome the Solid Tumor Microenvironment
I Navin, MT Lam, R Parihar |
Cancers | 2020 |
|
NK Cell-Based Immune Checkpoint Inhibition
M Khan, S Arooj, H Wang |
Frontiers in immunology | 2020 |
|
Hypoxia Impairs NK Cell Cytotoxicity through SHP-1-Mediated Attenuation of STAT3 and ERK Signaling Pathways
R Teng, Y Wang, N Lv, D Zhang, RA Williamson, L Lei, P Chen, L Lei, B Wang, J Fu, X Liu, A He, M ODwyer, J Hu |
Journal of Immunology Research | 2020 |
|
Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy
Y Yang, A Lundqvist |
Cancers | 2020 |
|
Memory-like natural killer cells for cancer immunotherapy
M Gang, P Wong, MM Berrien-Elliott, TA Fehniger |
Seminars in Hematology | 2020 |
|
Immunomodulatory effects of cytokine-induced expansion of cytotoxic lymphocytes in a mouse model of lupus-like disease
SD Reighard, D Krishnamurthy, H Cevik, DE Ochayon, A Ali, H Seelamneni, HI Brunner, SN Waggoner |
Cytotherapy | 2020 |
|
Blood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis
MR Mack, JR Brestoff, MM Berrien-Elliott, AM Trier, TL Yang, M McCullen, PL Collins, H Niu, ND Bodet, JA Wagner, E Park, AZ Xu, F Wang, R Chibnall, ML Council, C Heffington, F Kreisel, DJ Margolis, D Sheinbein, P Lovato, E Vivier, M Cella, M Colonna, WM Yokoyama, EM Oltz, TA Fehniger, BS Kim |
Science Translational Medicine | 2020 |
|
Potently Cytotoxic Natural Killer Cells Initially Emerge from Erythro-Myeloid Progenitors during Mammalian Development
C Dege, KH Fegan, JP Creamer, MM Berrien-Elliott, SA Luff, D Kim, JA Wagner, PD Kingsley, KE McGrath, TA Fehniger, J Palis, CM Sturgeon |
Developmental Cell | 2020 |
|
Obesity-Associated Alterations of Natural Killer Cells and Immunosurveillance of Cancer
I Bähr, J Spielmann, D Quandt, H Kielstein |
Frontiers in immunology | 2020 |
|
TRP Channels as Interior Designers: Remodeling the Endolysosomal Compartment in Natural Killer Cells
D Clement, JP Goodridge, C Grimm, S Patel, KJ Malmberg |
Frontiers in immunology | 2020 |
|
Identification of a Six-Immune-Related Long Non-coding RNA Signature for Predicting Survival and Immune Infiltrating Status in Breast Cancer
Z Li, Y Li, X Wang, Q Yang |
Frontiers in Genetics | 2020 |
|
CD56 regulates human NK cell cytotoxicity through Pyk2
JT Gunesch, AL Dixon, TA Ebrahim, MM Berrien-Elliott, S Tatineni, T Kumar, E Hegewisch-Solloa, TA Fehniger, EM Mace |
eLife | 2020 |
|
Natural Killer Cells in Immunotherapy: Are We Nearly There?
M Bachiller, AM Battram, L Perez-Amill, B Martín-Antonio |
Cancers | 2020 |
|
IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells
JM der Meer, RJ Maas, K Guldevall, K Klarenaar, PK de Jonge, JS Evert, AB van der Waart, J Cany, JT Safrit, JH Lee, E Wagena, P Friedl, B Önfelt, LF Massuger, NP Schaap, JH Jansen, W Hobo, H Dolstra |
Cancer Immunology, Immunotherapy | 2020 |
|
Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia
MM Berrien-Elliott, AF Cashen, CC Cubitt, CC Neal, P Wong, JA Wagner, M Foster, T Schappe, S Desai, E McClain, M Becker-Hapak, JA Foltz, ML Cooper, N Jaeger, SN Srivatsan, F Gao, R Romee, CN Abboud, GL Uy, P Westervelt, MA Jacoby, I Pusic, KE Stockerl-Goldstein, MA Schroeder, J DiPersio, TA Fehniger |
Cancer Discovery | 2020 |
|
Type 1 diabetes progression is associated with loss of CD3+CD56+ regulatory T cells that control CD8+ T-cell effector functions
G Terrazzano, S Bruzzaniti, V Rubino, M Santopaolo, AT Palatucci, A Giovazzino, CL Rocca, P de Candia, A Puca, F Perna, C Procaccini, VD Rosa, C Porcellini, SD Simone, V Fattorusso, A Porcellini, E Mozzillo, R Troncone, A Franzese, J Ludvigsson, G Matarese, G Ruggiero, M Galgani |
Nature metabolism | 2020 |
|
Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity
Rafei H, Daher M, Rezvani K |
British Journal of Haematology | 2020 |
|
Cytotoxicity of Human Hepatic Intrasinusoidal CD56bright Natural Killer Cells against Hepatocellular Carcinoma Cells
S Hwang, J Han, JS Baek, E Tak, GW Song, SG Lee, DH Jung, GC Park, CS Ahn, N Kim |
International journal of molecular sciences | 2019 |
|
TNF-α-induced Tim-3 expression marks the dysfunction of infiltrating natural killer cells in human esophageal cancer
Y Zheng, Y Li, J Lian, H Yang, F Li, S Zhao, Y Qi, Y Zhang, L Huang |
Journal of Translational Medicine | 2019 |
|
Exploiting NK Cell Surveillance Pathways for Cancer Therapy
A Barrow, M Colonna |
Cancers | 2019 |
|
The IRE1 endoplasmic reticulum stress sensor activates natural killer cell immunity in part by regulating c-Myc
H Dong, NM Adams, Y Xu, J Cao, DS Allan, JR Carlyle, , JC Sun, LH Glimcher |
Nature Immunology | 2019 |
|
Remodeling of secretory lysosomes during education tunes functional potential in NK cells
JP Goodridge, B Jacobs, ML Saetersmoen, D Clement, Q Hammer, T Clancy, E Skarpen, A Brech, J Landskron, C Grimm, A Pfefferle, L Meza-Zepeda, S Lorenz, MT Wiiger, WE Louch, EH Ask, LL Liu, VY Oei, U Kjällquist, S Linnarsson, S Patel, K Taskén, H Stenmark, KJ Malmberg |
Nature Communications | 2019 |
|
An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells
M Fantini, JM David, HC Wong, CM Annunziata, PM Arlen, KY Tsang |
Cancer Biotherapy & Radiopharmaceuticals | 2019 |
|
Loss-of-Function in SMAD4 Might Not Be Critical for Human Natural Killer Cell Responsiveness to TGF-β
LP Healy, GR Rossi, J Rautela, CA Slade, ND Huntington, IM Winship, F Souza-Fonseca-Guimaraes |
Frontiers in immunology | 2019 |
|
Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy
HG Yang, MC Kang, TY Kim, I Hwang, HT Jin, YC Sung, KS Eom, SW Kim |
Journal for ImmunoTherapy of Cancer | 2019 |
|
What Defines NK Cell Functional Fate: Phenotype or Metabolism?
SM Poznanski, AA Ashkar |
Frontiers in immunology | 2019 |
|
The miR-561-5p/CX 3 CL1 Signaling Axis Regulates Pulmonary Metastasis in Hepatocellular Carcinoma Involving CX 3 CR1 + Natural Killer Cells Infiltration
EB Chen, ZJ Zhou, K Xiao, GQ Zhu, Y Yang, B Wang, SL Zhou, Q Chen, D Yin, Z Wang, YH Shi, DM Gao, J Chen, Y Zhao, WZ Wu, J Fan, J Zhou, Z Dai |
Theranostics | 2019 |
|
CD56 Homodimerization and Participation in Anti-Tumor Immune Effector Cell Functioning: A Role for Interleukin-15
HH Acker, ZP Acker, M Versteven, P Ponsaerts, D Pende, ZN Berneman, S Anguille, VF Tendeloo, EL Smits |
Cancers | 2019 |
|
BCG Therapy of Bladder Cancer Stimulates a Prolonged Release of the Chemoattractant CXCL10 (IP10) in Patient Urine
O Ashiru, G Esteso, EM GarcíaCuesta, E Castellano, C Samba, E Escudero-López, S LópezCobo, M Álvarez-Maestro, A Linares, MM Ho, A Leibar, L MartínezPiñeiro, M ValésGómez |
Cancers | 2019 |
|
NK Cells as Potential Targets for Immunotherapy in Endometriosis
Ścieżyńska, Komorowski, Soszyńska, Malejczyk |
Journal of Clinical Medicine | 2019 |
|
Interleukin-15 Signaling in HIF-1α Regulation in Natural Killer Cells, Insights Through Mathematical Models
A Coulibaly, A Bettendorf, E Kostina, AS Figueiredo, SY Velásquez, HG Bock, M Thiel, HA Lindner, MV Barbarossa |
Frontiers in immunology | 2019 |
|
The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their ex vivo Expansion and Cytotoxic Potential Against Neuroblastoma: Perspective for Optimized Immunotherapy Post Haploidentical Stem Cell Transplantation
A Heinze, B Grebe, M Bremm, S Huenecke, TA Munir, L Graafen, JT Frueh, M Merker, E Rettinger, J Soerensen, T Klingebiel, P Bader, E Ullrich, C Cappel |
Frontiers in immunology | 2019 |
|
The early expansion of anergic NKG2Apos/CD56dim/CD16neg natural killer cells represents a therapeutic target in haploidentical haematopoietic stem cell transplantation
A Roberto, CD Vito, E Zaghi, EM Mazza, A Capucetti, M Calvi, P Tentorio, V Zanon, B Sarina, J Mariotti, S Bramanti, E Tenedini, E Tagliafico, S Bicciato, A Santoro, M Roederer, E Marcenaro, L Castagna, E Lugli, D Mavilio |
Haematologica | 2018 |
|
Emerging insights into human health and NK cell biology from the study of NK cell deficiencies
EM Mace, JS Orange |
Immunological Reviews | 2018 |
|
IL-15 Promotes Polyfunctional NK Cell Responses to Influenza by Boosting IL-12 Production
HR Wagstaffe, CM Nielsen, EM Riley, MR Goodier |
Journal of immunology (Baltimore, Md. : 1950) | 2018 |
|
Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes
KS Ivy, PB Ferrell |
Current Hematologic Malignancy Reports | 2018 |
|
Phosphoinositide-3-Kinase Signaling in Human Natural Killer Cells: New Insights from Primary Immunodeficiency
EM Mace |
Frontiers in immunology | 2018 |
|
Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types
KC Hicks, M Fantini, RN Donahue, A Schwab, KM Knudson, SR Tritsch, C Jochems, PE Clavijo, CT Allen, JW Hodge, KY Tsang, J Schlom, SR Gameiro |
OncoImmunology | 2018 |
|
Shining light on the significance of NK cell CD56 brightness
SM Poznanski, AA Ashkar |
Cellular and Molecular Immunology | 2018 |
|
One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy
L Besson, E Charrier, L Karlin, O Allatif, A Marçais, P Rouzaire, L Belmont, M Attal, C Lombard, G Salles, T Walzer, S Viel |
Frontiers in immunology | 2018 |
|
Roles of cytotoxic and helper innate lymphoid cells in cancer
C Guillerey |
Mammalian Genome | 2018 |
|
Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas
Y Liu, NS Sethi, T Hinoue, BG Schneider, AD Cherniack, F Sanchez-Vega, JA Seoane, F Farshidfar, R Bowlby, M Islam, J Kim, W Chatila, R Akbani, RS Kanchi, CS Rabkin, JE Willis, KK Wang, SJ McCall, L Mishra, AI Ojesina, S Bullman, CS Pedamallu, AJ Lazar, R Sakai, V Thorsson, AJ Bass, PW Laird, SJ Caesar-Johnson, JA Demchok, I Felau, M Kasapi, ML Ferguson, CM Hutter, HJ Sofia, R Tarnuzzer, Z Wang, L Yang, JC Zenklusen, JJ Zhang, S Chudamani, J Liu, L Lolla, R Naresh, T Pihl, Q Sun, Y Wan, Y Wu, J Cho, T DeFreitas, S Frazer, N Gehlenborg, G Getz, DI Heiman, J Kim, MS Lawrence, P Lin, S Meier, MS Noble, G Saksena, D Voet, H Zhang, B Bernard, N Chambwe, V Dhankani, T Knijnenburg, R Kramer, K Leinonen, Y Liu, M Miller, S Reynolds, I Shmulevich, V Thorsson, W Zhang, R Akbani, BM Broom, AM Hegde, Z Ju, RS Kanchi, A Korkut, J Li, H Liang, S Ling, W Liu, Y Lu, GB Mills, KS Ng, A Rao, M Ryan, J Wang, JN Weinstein, J Zhang, A Abeshouse, J Armenia, D Chakravarty, WK Chatila, I Bruijn, J Gao, BE Gross, ZJ Heins, R Kundra, K La, M Ladanyi, A Luna, MG Nissan, A Ochoa, SM Phillips, E Reznik, F Sanchez-Vega, C Sander, N Schultz, R Sheridan, SO Sumer, Y Sun, BS Taylor, J Wang, H Zhang, P Anur, M Peto, P Spellman, C Benz, JM Stuart, CK Wong, C Yau, DN Hayes, JS Parker, MD Wilkerson, A Ally, M Balasundaram, R Bowlby, D Brooks, R Carlsen, E Chuah, N Dhalla, R Holt, SJ Jones, K Kasaian, D Lee, Y Ma, MA Marra, M Mayo, RA Moore, AJ Mungall, K Mungall, AG Robertson, S Sadeghi, JE Schein, P Sipahimalani, A Tam, N Thiessen, K Tse, T Wong, AC Berger, R Beroukhim, AD Cherniack, C Cibulskis, SB Gabriel, GF Gao, G Ha, M Meyerson, SE Schumacher, J Shih, MH Kucherlapati, RS Kucherlapati, S Baylin, L Cope, L Danilova, MS Bootwalla, PH Lai, DT Maglinte, DJ Berg, DJ Weisenberger, JT Auman, S Balu, T Bodenheimer, C Fan, KA Hoadley, AP Hoyle, SR Jefferys, CD Jones, S Meng, PA Mieczkowski, LE Mose, AH Perou, CM Perou, J Roach, Y Shi, JV Simons, T Skelly, MG Soloway, D Tan, U Veluvolu, H Fan, T Hinoue, PW Laird, H Shen, W Zhou, M Bellair, K Chang, K Covington, CJ Creighton, H Dinh, HV Doddapaneni, LA Donehower, J Drummond, RA Gibbs, R Glenn, W Hale, Y Han, J Hu, V Korchina, S Lee, L Lewis, W Li, X Liu, M Morgan, D Morton, D Muzny, J Santibanez, M Sheth, E Shinbrot, L Wang, M Wang, DA Wheeler, , F Zhao, J Hess, EL Appelbaum, M Bailey, MG Cordes, L Ding, CC Fronick, LA Fulton, RS Fulton, C Kandoth, ER Mardis, MD McLellan, CA Miller, HK Schmidt, RK Wilson, D Crain, E Curley, J Gardner, K Lau, D Mallery, S Morris, J Paulauskis, R Penny, C Shelton, T Shelton, M Sherman, E Thompson, P Yena, J Bowen, JM Gastier-Foster, M Gerken, KM Leraas, TM Lichtenberg, NC Ramirez, L Wise, E Zmuda, N Corcoran, T Costello, C Hovens, AL Carvalho, AC de Carvalho, JH Fregnani, A Longatto-Filho, RM Reis, C Scapulatempo-Neto, HC Silveira, DO Vidal, A Burnette, J Eschbacher, B Hermes, A Noss, R Singh, ML Anderson, PD Castro, M Ittmann, D Huntsman, B Kohl, X Le, R Thorp, C Andry, ER Duffy, V Lyadov, O Paklina, G Setdikova, A Shabunin, M Tavobilov, C McPherson, R Warnick, R Berkowitz, D Cramer, C Feltmate, N Horowitz, A Kibel, M Muto, CP Raut, A Malykh, JS Barnholtz-Sloan, W Barrett, K Devine, J Fulop, QT Ostrom, K Shimmel, Y Wolinsky, AE Sloan, AD Rose, F Giuliante, M Goodman, BY Karlan, CH Hagedorn, J Eckman, J Harr, J Myers, K Tucker, LA Zach, B Deyarmin, H Hu, L Kvecher, C Larson, RJ Mural, S Somiari, A Vicha, T Zelinka, J Bennett, M Iacocca, B Rabeno, P Swanson, M Latour, L Lacombe, B Têtu, A Bergeron, M McGraw, SM Staugaitis, J Chabot, H Hibshoosh, A Sepulveda, T Su, T Wang, O Potapova, O Voronina, L Desjardins, O Mariani, S Roman-Roman, X Sastre, MH Stern, F Cheng, S Signoretti, A Berchuck, D Bigner, E Lipp, J Marks, S McCall, R McLendon, A Secord, A Sharp, M Behera, DJ Brat, A Chen, K Delman, S Force, F Khuri, K Magliocca, S Maithel, JJ Olson, T Owonikoko, A Pickens, S Ramalingam, DM Shin, G Sica, EG Meir, H Zhang, W Eijckenboom, A Gillis, E Korpershoek, L Looijenga, W Oosterhuis, H Stoop, KE van Kessel, EC Zwarthoff, C Calatozzolo, L Cuppini, S Cuzzubbo, F DiMeco, G Finocchiaro, L Mattei, A Perin, B Pollo, C Chen, J Houck, P Lohavanichbutr, A Hartmann, C Stoehr, R Stoehr, H Taubert, S Wach, B Wullich, W Kycler, D Murawa, M Wiznerowicz, K Chung, WJ Edenfield, J Martin, E Baudin, G Bubley, R Bueno, AD Rienzo, WG Richards, S Kalkanis, T Mikkelsen, H Noushmehr, L Scarpace, N Girard, M Aymerich, E Campo, E Giné, AL Guillermo, NV Bang, PT Hanh, BD Phu, Y Tang, H Colman, K Evason, PR Dottino, JA Martignetti, H Gabra, H Juhl, T Akeredolu, S Stepa, D Hoon, K Ahn, KJ Kang, F Beuschlein, A Breggia, M Birrer, D Bell, M Borad, AH Bryce, E Castle, V Chandan, J Cheville, JA Copland, M Farnell, T Flotte, N Giama, T Ho, M Kendrick, JP Kocher, K Kopp, C Moser, D Nagorney, D OBrien, BP ONeill, T Patel, G Petersen, F Que, M Rivera, L Roberts, R Smallridge, T Smyrk, M Stanton, RH Thompson, M Torbenson, JD Yang, L Zhang, F Brimo, JA Ajani, AM Gonzalez, C Behrens, J Bondaruk, R Broaddus, B Czerniak, B Esmaeli, J Fujimoto, J Gershenwald, C Guo, AJ Lazar, C Logothetis, F Meric-Bernstam, C Moran, L Ramondetta, D Rice, A Sood, P Tamboli, T Thompson, P Troncoso, A Tsao, I Wistuba, C Carter, L Haydu, P Hersey, V Jakrot, H Kakavand, R Kefford, K Lee, G Long, G Mann, M Quinn, R Saw, R Scolyer, K Shannon, A Spillane, J Stretch, M Synott, J Thompson, J Wilmott, H Al-Ahmadie, TA Chan, R Ghossein, A Gopalan, DA Levine, V Reuter, S Singer, B Singh, NV Tien, T Broudy, C Mirsaidi, P Nair, P Drwiega, J Miller, J Smith, H Zaren, JW Park, NP Hung, E Kebebew, WM Linehan, AR Metwalli, K Pacak, PA Pinto, M Schiffman, LS Schmidt, CD Vocke, N Wentzensen, R Worrell, H Yang, M Moncrieff, C Goparaju, J Melamed, H Pass, N Botnariuc, I Caraman, M Cernat, I Chemencedji, A Clipca, S Doruc, G Gorincioi, S Mura, M Pirtac, I Stancul, D Tcaciuc, M Albert, I Alexopoulou, A Arnaout, J Bartlett, J Engel, S Gilbert, J Parfitt, H Sekhon, G Thomas, DM Rassl, RC Rintoul, C Bifulco, R Tamakawa, W Urba, N Hayward, H Timmers, A Antenucci, F Facciolo, G Grazi, M Marino, R Merola, R de Krijger, AP Gimenez-Roqueplo, A Piché, S Chevalier, G McKercher, K Birsoy, G Barnett, C Brewer, C Farver, T Naska, NA Pennell, D Raymond, C Schilero, K Smolenski, F Williams, C Morrison, JA Borgia, MJ Liptay, M Pool, CW Seder, K Junker, L Omberg, M Dinkin, G Manikhas, D Alvaro, MC Bragazzi, V Cardinale, G Carpino, E Gaudio, D Chesla, S Cottingham, M Dubina, F Moiseenko, R Dhanasekaran, KF Becker, KP Janssen, J Slotta-Huspenina, MH Abdel-Rahman, D Aziz, S Bell, CM Cebulla, A Davis, R Duell, J Bradley, J Hilty, B Kumar, J Lang, NL Lehman, R Mandt, P Nguyen, R Pilarski, K Rai, L Schoenfield, K Senecal, P Wakely, P Hansen, R Lechan, J Powers, A Tischler, WE Grizzle, KC Sexton, A Kastl, J Henderson, S Porten, J Waldmann, M Fassnacht, SL Asa, D Schadendorf, M Couce, M Graefen, H Huland, G Sauter, T Schlomm, R Simon, P Tennstedt, O Olabode, M Nelson, O Bathe, PR Carroll, JM Chan, P Disaia, P Glenn, RK Kelley, CN Landen, J Phillips, M Prados, J Simko, K Smith-McCune, S VandenBerg, K Roggin, A Fehrenbach, A Kendler, S Sifri, R Steele, A Jimeno, F Carey, I Forgie, M Mannelli, M Carney, B Hernandez, B Campos, C Herold-Mende, C Jungk, A Unterberg, A von Deimling, A Bossler, J Galbraith, L Jacobus, M Knudson, T Knutson, D Ma, M Milhem, R Sigmund, AK Godwin, R Madan, HG Rosenthal, C Adebamowo, SN Adebamowo, A Boussioutas, D Beer, T Giordano, AM Mes-Masson, F Saad, T Bocklage, L Landrum, R Mannel, K Moore, K Moxley, R Postier, J Walker, R Zuna, M Feldman, F Valdivieso, R Dhir, J Luketich, EM Pinero, M Quintero-Aguilo, CG Carlotti, JS Santos, R Kemp, A Sankarankuty, D Tirapelli, J Catto, K Agnew, E Swisher, J Creaney, B Robinson, CS Shelley, EM Godwin, S Kendall, C Shipman, C Bradford, T Carey, A Haddad, J Moyer, L Peterson, M Prince, L Rozek, G Wolf, R Bowman, KM Fong, I Yang, R Korst, WK Rathmell, JL Fantacone-Campbell, JA Hooke, AJ Kovatich, CD Shriver, J DiPersio, B Drake, R Govindan, S Heath, T Ley, BV Tine, P Westervelt, MA Rubin, JI Lee, ND Aredes, A Mariamidze |
Cancer Cell | 2018 |
|
Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs
Y Ren, M Korom, R Truong, D Chan, SH Huang, CC Kovacs, E Benko, JT Safrit, J Lee, H Garbán, R Apps, H Goldstein, RM Lynch, RB Jones, G Silvestri |
Journal of virology | 2018 |
|
Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy
E García-Martínez, M Smith, A Buqué, F Aranda, FA de la Peña, A Ivars, MS Cánovas, MA Conesa, J Fucikova, R Spisek, L Zitvogel, G Kroemer, L Galluzzi |
OncoImmunology | 2018 |
|
IL-15 STIMULATED NATURAL KILLER CELLS CLEAR HIV-1 INFECTED CELLS FOLLOWING LATENCY REVERSAL EX VIVO
C Garrido, M Abad-Fernandez, M Tuyishime, JJ Pollara, G Ferrari, N Soriano-Sarabia, DM Margolis |
Journal of virology | 2018 |
|
Implication of Interleukin-12/15/18 and Ruxolitinib in the Phenotype, Proliferation, and Polyfunctionality of Human Cytokine-Preactivated Natural Killer Cells
I Terrén, I Mikelez, I Odriozola, A Gredilla, J González, A Orrantia, J Vitallé, O Zenarruzabeitia, F Borrego |
Frontiers in immunology | 2018 |
|
The natural product chitosan enhances the anti-tumor activity of natural killer cells by activating dendritic cells
X Li, W Dong, AP Nalin, Y Wang, P Pan, B Xu, Y Zhang, S Tun, J Zhang, LS Wang, X He, MA Caligiuri, J Yu |
OncoImmunology | 2018 |
|
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
R Romee, S Cooley, MM Berrien-Elliott, P Westervelt, MR Verneris, JE Wagner, DJ Weisdorf, BR Blazar, C Ustun, TE DeFor, S Vivek, L Peck, JF DiPersio, AF Cashen, R Kyllo, A Musiek, A Schaffer, MJ Anadkat, I Rosman, D Miller, JO Egan, EK Jeng, A Rock, HC Wong, TA Fehniger, JS Miller |
Blood | 2018 |
|
TGFβ Imprinting During Activation Promotes Natural Killer Cell Cytokine Hypersecretion
J Foltz, J Moseman, A Thakkar, N Chakravarti, D Lee |
Cancers | 2018 |
|
In the absence of natural killer cell activation donor-specific antibody mediates chronic, but not acute, kidney allograft rejection
T Yagisawa, T Tanaka, S Miyairi, K Tanabe, N Dvorina, WM Yokoyama, A Valujskikh, WM rd, RL Fairchild |
Kidney International | 2018 |
|
Intratumoral CD56bright natural killer cells are associated with improved survival in bladder cancer
N Mukherjee, N Ji, V Hurez, TJ Curiel, MO Montgomery, AJ Braun, M Nicolas, M Aguilera, D Kaushik, Q Liu, J Ruan, KA Kendrick, RS Svatek |
Oncotarget | 2018 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)